Improving Patient Participation Through Pre-Consultation Education
Stealth efficacy has improved as a result of interventions to enhance stealth care. Trials investigating lifestyle interventions in a variety of illnesses including diabetes, coronary heart disease, heart failure, and rheumatoid arthritis have shown chronicle improvements.
How relevant is the content of this newsletter to you?
MAT-IN-2400628-v1.0-4/24
leave-site-modal-text
You are now being redirected to a third-party website.
Sanofi does not endorse or approve the content, products, services or opinions on the third-party website. Sanofi shall not be responsible or in any way liable for any injury or damage to any persons in view of any reliance placed on or action taken basis of the information on the third party website or any errors, omissions or inaccuracies and/or incompleteness of the information on the third party website.
Right answer: Both A and B. As per Diabetic & Ramadan guidelines, T2DM patients can safely continue glargine U-100 once daily at a reduced dose of 15 - 30% at Iftar1,2. Insulin glargine U-100 is safe to be used during Ramadan with no significant increase in hypoglycaemia3. One-on-one dietary educational session can also reduce the number of adverse events of fasting1.
